<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048879</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00033929</org_study_id>
    <nct_id>NCT01048879</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)</brief_title>
  <official_title>Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving CVVHD and/or ECMO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Critically ill patients with flu may receive a drug called oseltamivir. They may also receive
      medical therapies to support their lung function (extracorporeal membrane oxygenation; ECMO)
      and kidney function (continuous venovenous hemodialysis; CVVHD). CVVHD and ECMO may remove
      some oseltamivir from the bloodstream. The purpose of this study is to determine how much
      oseltamivir gets removed by CVVHD or ECMO in critically ill patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous Venovenous Hemodialysis (CVVHD)Oseltamivir Carboxylate Transmembrane Clearance</measure>
    <time_frame>12 hours</time_frame>
    <description>Oseltamivir Carboxylate Transmembrane Clearance by Continuous Venovenous Hemodialysis (Reported in mL/min).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oseltamivir Carboxylate Removal by ECMO</measure>
    <time_frame>12 hours</time_frame>
    <description>Mean percent change in oseltamivir carboxylate concentration pre- and post-oxygenator.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Critically Ill Renal Failure Requiring CVVHD and Oseltamivir</condition>
  <condition>Critically Ill Requiring ECMO and Oseltamivir</condition>
  <arm_group>
    <arm_group_label>ECMO alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients receiving oseltamivir and Extracorporeal Membrane Oxygenation (ECMO) therapy (patients were already receiving oseltamivir and ECMO due to an illness)- Procedure/Surgery: pharmacokinetic blood sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVVHD Alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients receiving Continuous Venovenous Hemodialysis(CVVHD) and oseltamivir (Patients were already receiving oseltamivir and CVVHD as a result of an illness).
Procedure/Surgery: pharmacokinetic blood and dialysate sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVVHD + ECMO</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receiving oseltamivir and ECMO and CVVHD (patients were already receiving oseltamivir, ECMO, and CVVHD as part of an illness).
Procedure/Surgery: pharmacokinetic blood and dialysate sampling</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pharmacokinetic blood sampling</intervention_name>
    <description>blood samples collected to assess oseltamivir concentrations</description>
    <arm_group_label>ECMO alone</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pharmacokinetic blood and dialysate sampling</intervention_name>
    <description>blood and dialysate samples collected and assayed for oseltamivir concentrations</description>
    <arm_group_label>CVVHD Alone</arm_group_label>
    <arm_group_label>CVVHD + ECMO</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  receiving Continuous Venovenous Hemodialysis (CVVHD) or Extracorporeal Membrane
             Oxygenation (ECMO)

          -  require oseltamivir treatment

          -  informed consent granted

        Exclusion Criteria:

          -  pregnant

          -  unable to complete 12 hours of CVVHD or ECMO

          -  &lt;6 kg body weight

          -  allergy to oseltamivir
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce A Mueller, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <results_first_submitted>June 13, 2012</results_first_submitted>
  <results_first_submitted_qc>July 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2012</results_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Bruce A. Mueller</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>oseltamivir</keyword>
  <keyword>influenza</keyword>
  <keyword>continuous renal replacement therapy</keyword>
  <keyword>extracorporeal membrane oxygenation</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ECMO Alone</title>
          <description>Patients receiving oseltamivir and Extracorporeal Membrane Oxygenation (ECMO) therapy</description>
        </group>
        <group group_id="P2">
          <title>CVVHD Alone</title>
          <description>Patients receiving Continuous Venovenous Hemodialysis(CVVHD) and oseltamivir</description>
        </group>
        <group group_id="P3">
          <title>CVVHD + ECMO</title>
          <description>Patient receiving oseltamivir and ECMO and CVVHD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ECMO Alone</title>
          <description>Patients receiving oseltamivir and Extracorporeal Membrane Oxygenation (ECMO) therapy</description>
        </group>
        <group group_id="B2">
          <title>CVVHD Alone</title>
          <description>Patients receiving Continuous Venovenous Hemodialysis(CVVHD) and oseltamivir</description>
        </group>
        <group group_id="B3">
          <title>CVVHD + ECMO</title>
          <description>Patient receiving oseltamivir and ECMO and CVVHD</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="0"/>
                    <measurement group_id="B2" value="33.0" spread="10.2"/>
                    <measurement group_id="B3" value="32.2" spread="16.1"/>
                    <measurement group_id="B4" value="33.8" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Continuous Venovenous Hemodialysis (CVVHD)Oseltamivir Carboxylate Transmembrane Clearance</title>
        <description>Oseltamivir Carboxylate Transmembrane Clearance by Continuous Venovenous Hemodialysis (Reported in mL/min).</description>
        <time_frame>12 hours</time_frame>
        <population>One patient in the CVVHD Alone group was excluded from the analysis because not enough data points were available for pharmacokinetic modeling.</population>
        <group_list>
          <group group_id="O1">
            <title>CVVHD Alone</title>
            <description>Patients receiving Continuous Venovenous Hemodialysis(CVVHD) and oseltamivir</description>
          </group>
          <group group_id="O2">
            <title>CVVHD + ECMO</title>
            <description>Patients receiving oseltamivir and ECMO and CVVHD</description>
          </group>
          <group group_id="O3">
            <title>ECMO Alone</title>
            <description>Patients receiving ECMO only</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Venovenous Hemodialysis (CVVHD)Oseltamivir Carboxylate Transmembrane Clearance</title>
          <description>Oseltamivir Carboxylate Transmembrane Clearance by Continuous Venovenous Hemodialysis (Reported in mL/min).</description>
          <population>One patient in the CVVHD Alone group was excluded from the analysis because not enough data points were available for pharmacokinetic modeling.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" spread="8.0"/>
                    <measurement group_id="O2" value="43.3" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oseltamivir Carboxylate Removal by ECMO</title>
        <description>Mean percent change in oseltamivir carboxylate concentration pre- and post-oxygenator.</description>
        <time_frame>12 hours</time_frame>
        <population>All of the patients that received ECMO were included. Patients receiving CVVHD Alone did not receive ECMO and were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>CVVHD Alone</title>
            <description>Patients receiving Continuous Venovenous Hemodialysis(CVVHD) and oseltamivir</description>
          </group>
          <group group_id="O2">
            <title>CVVHD + ECMO</title>
            <description>Patients receiving oseltamivir and ECMO and CVVHD</description>
          </group>
          <group group_id="O3">
            <title>ECMO Alone</title>
            <description>Patients receiving ECMO only</description>
          </group>
        </group_list>
        <measure>
          <title>Oseltamivir Carboxylate Removal by ECMO</title>
          <description>Mean percent change in oseltamivir carboxylate concentration pre- and post-oxygenator.</description>
          <population>All of the patients that received ECMO were included. Patients receiving CVVHD Alone did not receive ECMO and were not included.</population>
          <units>percent change in concentration</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.008" spread="0.101"/>
                    <measurement group_id="O3" value="-0.033" spread="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ECMO Alone</title>
          <description>Patients receiving oseltamivir and Extracorporeal Membrane Oxygenation (ECMO) therapy</description>
        </group>
        <group group_id="E2">
          <title>CVVHD Alone</title>
          <description>Patients receiving Continuous Venovenous Hemodialysis(CVVHD) and oseltamivir</description>
        </group>
        <group group_id="E3">
          <title>CVVHD + ECMO</title>
          <description>Patient receiving oseltamivir and ECMO and CVVHD</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bruce A. Mueller</name_or_title>
      <organization>University of Michigan</organization>
      <phone>7346154578</phone>
      <email>muellerb@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

